EZH2 and acute myeloid leukemia: Here, except for MDS-derived AML, an analysis of 714 patients found that the frequency of EZH2 mutations was only 1.8% in de novo AML (Wang et al., 2013), and this reflected uncertainties in the prevalence and prognostic value of EZH2 mutations in AML individuals.